Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 406

Sort by

Sort Order Select

Journal Articles

Impact of Adding Melphalan to Fludarabine and a Myeloablative Dose of Intravenous Busulfan for Patients Who Received Allogeneic Hematopoietic Stem Cell Transplantation

Yoshimitsu Shimomura, Masahiko Hara, MD PhD, Hisashi Yamamoto, MD PhD, Tatsuo Ichinohe, Takahiro Fukuda, Minoko Takanashi, MD PhD, Yoshiko Atsuta, MD PhD, Takayuki Ishikawa, MD PhD

Blood (2019) 134 (Supplement_1): 254.

https://doi.org/10.1182/blood-2019-125470

Published: 2019

Journal Articles

Anabolic Steroids in Myelodysplastic Syndromes: A Systematic Review

Alejandro Garcia-Horton, MDFRCPC, Yashoda Valliere, Alejandro Lazo-Langner, MD MSc

Blood (2019) 134 (Supplement_1): 5425.

https://doi.org/10.1182/blood-2019-126806

Published: 2019

Journal Articles

Pegylated Interferon in Myelodysplastic/Myeloproliferative Syndrome with Ringsideroblasts and Thrombocytosis

Rudolf A. Benz, MD, Kathrin Zimmermann, Corinne C Widmer, MD MSc

Blood (2019) 134 (Supplement_1): 5433.

https://doi.org/10.1182/blood-2019-129077

Published: 2019

Journal Articles

Next Generation Sequencing and Microrna Assay in a Cohort of Patients Affected By Myelodysplastic Syndromes. an Analysis of Clinical and Genotypic Features

Daniele Avenoso, MD, Margherita Squillario, Annalisa Barla, Alessandro Verri, Enrico Carminati, Clara Nurra, Elisabetta Todisco, MD PhD, Federica Gigli, MD, Giuliana Gregato, Claudia Poletti, Francesco Bertolini, MD PhD, Ghulam J. Mufti, MBBS, FRCP, FRCPath, DM, Mili Shah, FRCPath, Maurizio Miglino

Blood (2019) 134 (Supplement_1): 5414.

https://doi.org/10.1182/blood-2019-130153

Published: 2019

Journal Articles

Impact of HFE gene Variants on Iron Overload, Overall Survival and Leukemia-Free Survival in Myelodysplastic Syndromes

Mathias A. Schneeweiss, Greiner Georg, MD PhD, Susanne Herndlhofer, Julia Schellnegger, Maria-Theresa Krauth, MD, Friedrich Wimazal, MD, Corinna Steinhauser, Renate Thalhammer, MD, Ilse Schwarzinger, MD, Harald Esterbauer, MD PhD, Manuela Födinger, Peter Valent, MD, Wolfgang R. Sperr, MD

Blood (2019) 134 (Supplement_1): 4269.

https://doi.org/10.1182/blood-2019-123390

Published: 2019

Journal Articles

Luspatercept Significantly Reduces Red Blood Cell (RBC) Transfusion Burden, Regardless of Gene Mutation Frequency, Spectrum, and Prognostic Significance, Among Patients (Pts) with LR-MDS Enrolled in the MEDALIST Trial

Blood (2019) 134 (Supplement_1): 2999.

https://doi.org/10.1182/blood-2019-123655

Published: 2019

Journal Articles

Phosphorus Levels in Iron Deficient Children Treated with Ferric Carboxymaltose

Susan Kirk, PA-C, Donald Mahoney, MD, Melanie Brooke Bernhardt, PharmD, Jacquelyn M. Powers, MD,MSc

Blood (2019) 134 (Supplement_1): 2240.

https://doi.org/10.1182/blood-2019-129159

Published: 2019

Journal Articles

De Novo and Therapy-Related Acute Myeloid Leukemia and Myelodysplastic Syndrome: Similarities and Differences in SNP-Array Detected Chromosomal Aberrations in Pre-Transplant Blood Samples

Blood (2019) 134 (Supplement_1): 1430.

https://doi.org/10.1182/blood-2019-129110

Published: 2019

Journal Articles

A Phase I Study of CC-90002, a Monoclonal Antibody Targeting CD47, in Patients with Relapsed and/or Refractory (R/R) Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS): Final Results

Amer M. Zeidan, MBBS, MHS, Daniel J. DeAngelo, MD PhD, Jeanne M. Palmer, Christopher S. Seet, MD PhD, Martin S. Tallman, MD, Xin Wei, PhD, Ying Fei Li, PhD, Nanette Hock, RN, MSN, Michael R. Burgess, Kristen Hege, Wendy Stock, MD

Blood (2019) 134 (Supplement_1): 1320.

https://doi.org/10.1182/blood-2019-125363

Published: 2019

Journal Articles

Clinical Effectiveness of Hypomethylating Agents (HMAs) and Lenalidomide (Len) in Older Patients (pts) with Refractory Anemia with Ring Sideroblasts: A Large Population-Based Study in the United States (US)

Xiaoyi Wang, MD MPH, Rong Wang, PhD, Chi Zhang, MD MPH, Amer M. Zeidan, MBBS, MHS, Nikolai A. Podoltsev, MD PhD, Scott F. Huntington, MD MPH, Steven D. Gore, MD, Amy J Davidoff, PhD MS, Xiaomei Ma, PhD

Blood (2019) 134 (Supplement_1): 4748.

https://doi.org/10.1182/blood-2019-128821

Published: 2019

Journal Articles

Lenalidomide Is Effective Treatment Option for Patients with Refractory Anemia with Ring Sideroblasts and Thrombocytosis

Megan Melody, BA, MS, Najla Al Ali, M.Sc, David A Sallman, MD, Eric Padron, MD, Alan F. List, MD, Jeffrey E. Lancet, MD, Rami S. Komrokji, MD

Blood (2018) 132 (Supplement 1): 4383.

https://doi.org/10.1182/blood-2018-99-110237

Published: 2018

Journal Articles

Percentage of Erythroid Cells in Bone Marrow at Diagnosis As a New Prognostic Factor in Patients with Myelodysplastic Syndrome

Blood (2018) 132 (Supplement 1): 4363.

https://doi.org/10.1182/blood-2018-99-110210

Published: 2018

Journal Articles

MDS/Secondary AML Associated with Type I Gaucher Disease

Atsushi Okamoto, MD, Kenta Yamamoto, Go Eguchi, Yoshitaka Kanai, Terufumi Yamaguchi, Yasuhiro Maeda, MD PhD

Blood (2018) 132 (Supplement 1): 5193.

https://doi.org/10.1182/blood-2018-99-116058

Published: 2018

Journal Articles

Generation and Molecular Characterization of Human Ring Sideroblasts

Kei Saito, Tohru Fujiwara, MD PhD, Shunsuke Hatta, Chie Suzuki, Noriko Fukuhara, MD PhD, Yasushi Onishi, MD PhD, Yukio Nakamura, MD PhD, Hideo Harigae, MD

Blood (2018) 132 (Supplement 1): 3613.

https://doi.org/10.1182/blood-2018-99-111066

Published: 2018

Journal Articles

A Novel Metabolic Transcriptome Identified in Myelodysplastic Syndromes (MDS) Correlates with OMS Classification and Poor Prognosis

Christophe Desterke, Estelle Balducci, Xavier Fund, Claire Borie, Annelise Bennaceur-Griscelli, MD PhD, Ali G Turhan, MD PhD

Blood (2018) 132 (Supplement 1): 5495.

https://doi.org/10.1182/blood-2018-99-110678

Published: 2018

Journal Articles

Characteristics and Role of Lenalidomide Therapy in Patients with Myelodysplastic/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis

Kiran Naqvi, MD MPH, Koji Sasaki, MD, Guillermo Montalban-Bravo, MD, Michael S Teach, Sherry A. Pierce, BSN, BA, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD

Blood (2018) 132 (Supplement 1): 5513.

https://doi.org/10.1182/blood-2018-99-117266

Published: 2018

Journal Articles

Impact of Red Cell Distribution Width on Dysplasia and Clinical Outcome in 66 Patients with Myelodysplastic Syndrome without Increased Blasts

Yuta Baba, PhD MD, Bungo Saito, MD PhD, Shotaro Shimada, MD, Yohei Sasaki, MD, So Murai, MD, Maasa Abe, MD, Shun Fujiwara, MD, Nana Arai, MD, Yukiko Kawaguchi, MD, Nobuyuki Kabasawa, MD, Hiroyuki Tsukamoto, MD PhD, Yui Uto, MD PhD, Kouji Yanagisawa, MD, Norimichi Hattori, MD PhD, Hiroshi Harada, MD, Tsuyoshi Nakamaki, MD PhD

Blood (2018) 132 (Supplement 1): 5522.

https://doi.org/10.1182/blood-2018-99-113973

Published: 2018

Journal Articles

Hepcidin and Erythroferrone in the Anemia of Low-Risk Myelodysplastic Syndromes

Gillen Oarbeascoa, MD, Sara Redondo, MD, Maria Jose Morán-Jiménez, MD, Amalia Domingo, MD, Cristina Muñoz-Linares, MD, Maria Isabel Moreno-Carralero, MD, Jose Maria Bellon, Juan Francisco del Campo Rincon, MD, Jose Luis Díez-Martín, MD PhD, Patricia Font, MD

Blood (2018) 132 (Supplement 1): 3085.

https://doi.org/10.1182/blood-2018-99-116992

Published: 2018

Journal Articles

Loss-of-Function Mutation in tet2 in Zebrafish Leads to Early MDS like Phenotype

Vinothkumar Rajan, BS, Rachel Woodside, B.SC, Sergey V Prykhozhij, PhD, Jason Berman, MD

Blood (2018) 132 (Supplement 1): 2318.

https://doi.org/10.1182/blood-2018-99-118594

Published: 2018

Journal Articles

Assessing Needs for Support in MDS Patients

Esther Natalie Oliva, MD, Raqeebah Agberemi, Sophie Wintrich

Blood (2018) 132 (Supplement 1): 2313.

https://doi.org/10.1182/blood-2018-99-112967

Published: 2018

NARROW

Impact of Adding Melphalan to Fludarabine and a Myeloablative Dose of Intravenous Busulfan for Patients Who Received Allogeneic Hematopoietic Stem Cell Transplantation

Anabolic Steroids in Myelodysplastic Syndromes: A Systematic Review

Pegylated Interferon in Myelodysplastic/Myeloproliferative Syndrome with Ringsideroblasts and Thrombocytosis

Next Generation Sequencing and Microrna Assay in a Cohort of Patients Affected By Myelodysplastic Syndromes. an Analysis of Clinical and Genotypic Features

Impact of HFE gene Variants on Iron Overload, Overall Survival and Leukemia-Free Survival in Myelodysplastic Syndromes

Luspatercept Significantly Reduces Red Blood Cell (RBC) Transfusion Burden, Regardless of Gene Mutation Frequency, Spectrum, and Prognostic Significance, Among Patients (Pts) with LR-MDS Enrolled in the MEDALIST Trial

Phosphorus Levels in Iron Deficient Children Treated with Ferric Carboxymaltose

De Novo and Therapy-Related Acute Myeloid Leukemia and Myelodysplastic Syndrome: Similarities and Differences in SNP-Array Detected Chromosomal Aberrations in Pre-Transplant Blood Samples

A Phase I Study of CC-90002, a Monoclonal Antibody Targeting CD47, in Patients with Relapsed and/or Refractory (R/R) Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS): Final Results

Clinical Effectiveness of Hypomethylating Agents (HMAs) and Lenalidomide (Len) in Older Patients (pts) with Refractory Anemia with Ring Sideroblasts: A Large Population-Based Study in the United States (US)

Lenalidomide Is Effective Treatment Option for Patients with Refractory Anemia with Ring Sideroblasts and Thrombocytosis

Percentage of Erythroid Cells in Bone Marrow at Diagnosis As a New Prognostic Factor in Patients with Myelodysplastic Syndrome

MDS/Secondary AML Associated with Type I Gaucher Disease

Generation and Molecular Characterization of Human Ring Sideroblasts

A Novel Metabolic Transcriptome Identified in Myelodysplastic Syndromes (MDS) Correlates with OMS Classification and Poor Prognosis

Characteristics and Role of Lenalidomide Therapy in Patients with Myelodysplastic/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis

Impact of Red Cell Distribution Width on Dysplasia and Clinical Outcome in 66 Patients with Myelodysplastic Syndrome without Increased Blasts

Hepcidin and Erythroferrone in the Anemia of Low-Risk Myelodysplastic Syndromes

Loss-of-Function Mutation in tet2 in Zebrafish Leads to Early MDS like Phenotype

Assessing Needs for Support in MDS Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only